This page shows the latest Rybelsus news and features for those working in and with pharma, biotech and healthcare.
Also within Novo’s roster is an oral formulation of semaglutide – marketed under the Rybelsus brand name – that is authorised for the treatment of type 2 diabetes.
Following the acquisition deal completion, Novo will pick up Emisphere’s drug delivery technology – Eligen SNAC – which it uses in its oral diabetes drug Rybelsus (oral semaglutide). ... Novo won US Food and Drug Administration (FDA) approval for
Novo also has Rybelsus – oral semaglutide – in its arsenal, and analysts at Pareto Securities have suggested that demand for an oral alternative GLP-1 could make the drug a $5.4bn
Novo also reported sales of DKK50m for its recently launched oral semaglutide product Rybelsus in the quarter – the company has said it is encouraged by the early performance of the drug, ... The Rybelsus launch in the US is off to a good start, and
Joining Givlaari with a positive recommendation was Rybelsus (semaglutide), Novo Nordisk’s once-daily oral formulation of its injectable GLP-1 agonist semaglutide. ... In Novo’s Pioneer programme of the drug, people treated with Rybelsus achieved
Otherwise, it is also conducting a dedicated cardiovascular outcomes trial for Rybelsus – SOUL – that is due to generate data in 2024. ... Some market predictors think Rybelsus could go even higher if the SOUL data is competitive.
More from news
Approximately 4 fully matching, plus 4 partially matching documents found.
Meanwhile, Novo Nordisk has launched Rybelsus (semaglutide) oral tablets to improve control of blood sugar – but specifically alongside diet and exercise.
7. NovoNordisk’s Rybelsus is an oral once-daily formulation of semaglutide, a long-acting glucagon-like peptide (GLP)-1 analog. ... Rybelsus is available in the US to improve glycaemic control in adults with type 2 diabetes.
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...